Artículos

Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine / Marcus W. Agelink en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 8-13 Título : Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine Tipo de documento: texto impreso Autores: Marcus W. Agelink, Autor ; Tomasz Majewski, Autor Fecha de publicación: 2023 Artículo en la página: pp. 8-13 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Sistema Nervioso Autónomo, Benzodiazepinas, Electrocardiografía, Frecuencia cardiaca, Olanzapina, Pirenzepina. Resumen: As part of a prospective clinical study investigating the effects of atypical neuroleptics on autonomic neurocardiac function (ANF), serial standardized recordings of conventional electrocardiograms and computer-calculated measurements of 5-minute resting heart rate variability (HRV) were obtained from 51 medication-free inpatients with schizophrenia (DSM-III-R-diagnosed) before and after an average of 14.1 days of treatment with amisulpride 400 mg/day (N = 12), olanzapine 20 mg/day (N = 13), sertindole 12 mg/day (N = 13), or clozapine 100 mg/day (N = 13). Link: ./index.php?lvl=notice_display&id=31131 [artículo] Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine [texto impreso] / Marcus W. Agelink, Autor ; Tomasz Majewski, Autor . - 2023 . - pp. 8-13. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 8-13 Palabras clave: Antipsicóticos, Sistema Nervioso Autónomo, Benzodiazepinas, Electrocardiografía, Frecuencia cardiaca, Olanzapina, Pirenzepina. Resumen: As part of a prospective clinical study investigating the effects of atypical neuroleptics on autonomic neurocardiac function (ANF), serial standardized recordings of conventional electrocardiograms and computer-calculated measurements of 5-minute resting heart rate variability (HRV) were obtained from 51 medication-free inpatients with schizophrenia (DSM-III-R-diagnosed) before and after an average of 14.1 days of treatment with amisulpride 400 mg/day (N = 12), olanzapine 20 mg/day (N = 13), sertindole 12 mg/day (N = 13), or clozapine 100 mg/day (N = 13). Link: ./index.php?lvl=notice_display&id=31131

Olanzapine plasma concentrations and clinical response: acute phase results of the north american olanzapine trial / Paul J. Perry en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 14-20 Título : Olanzapine plasma concentrations and clinical response: acute phase results of the north american olanzapine trial Tipo de documento: texto impreso Autores: Paul J. Perry, Autor ; Brian C. Lund, Autor ; Todd Sanger, Autor Fecha de publicación: 2023 Artículo en la página: pp. 14-20 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Benzodiazepinas, Pirenzepina, Esquizofrenia. Resumen: Olanzapine is an atypical antipsychotic that is effective in the treatment of schizophrenia. Olanzapine plasma concentrations ≥ 9.3 ng/mL (24 hours postdose) have been identified as a predictor of clinical response in acutely ill patients with schizophrenia. The authors report a receiver operating characteristic (ROC) curve analysis of 12-hour olanzapine concentrations and treatment response from the North American Double-Blind Olanzapine Trial. Link: ./index.php?lvl=notice_display&id=31132 [artículo] Olanzapine plasma concentrations and clinical response: acute phase results of the north american olanzapine trial [texto impreso] / Paul J. Perry, Autor ; Brian C. Lund, Autor ; Todd Sanger, Autor . - 2023 . - pp. 14-20. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 14-20 Palabras clave: Antipsicóticos, Benzodiazepinas, Pirenzepina, Esquizofrenia. Resumen: Olanzapine is an atypical antipsychotic that is effective in the treatment of schizophrenia. Olanzapine plasma concentrations ≥ 9.3 ng/mL (24 hours postdose) have been identified as a predictor of clinical response in acutely ill patients with schizophrenia. The authors report a receiver operating characteristic (ROC) curve analysis of 12-hour olanzapine concentrations and treatment response from the North American Double-Blind Olanzapine Trial. Link: ./index.php?lvl=notice_display&id=31132

Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications / Adel Wassef en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 21-26 Título : Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications Tipo de documento: texto impreso Autores: Adel Wassef, Autor ; Nadir G. Hafiz, Autor ; Delilah Hampton, Autor Fecha de publicación: 2023 Artículo en la página: pp. 21-26 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Farmacoterapia, Haloperidol, Hospitalización, Esquizofrenia. Resumen: Divalproex sodium has been approved for use in treating bipolar disorder. Its usefulness in schizophrenia has yet to be adequately assessed. Three days after initiating haloperidol treatment, patients who were hospitalized for an acute exacerbation of schizophrenia received either valproate augmentation (early-augmentation group) or continued to receive haloperidol alone (no-augmentation group). Link: ./index.php?lvl=notice_display&id=31133 [artículo] Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications [texto impreso] / Adel Wassef, Autor ; Nadir G. Hafiz, Autor ; Delilah Hampton, Autor . - 2023 . - pp. 21-26. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 21-26 Palabras clave: Antipsicóticos, Farmacoterapia, Haloperidol, Hospitalización, Esquizofrenia. Resumen: Divalproex sodium has been approved for use in treating bipolar disorder. Its usefulness in schizophrenia has yet to be adequately assessed. Three days after initiating haloperidol treatment, patients who were hospitalized for an acute exacerbation of schizophrenia received either valproate augmentation (early-augmentation group) or continued to receive haloperidol alone (no-augmentation group). Link: ./index.php?lvl=notice_display&id=31133

Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies / Paul E. Keck en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 27-35 Título : Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies Tipo de documento: texto impreso Autores: Paul E. Keck, Autor ; Karen R. Reeves, Autor ; Edmund P. Harrigan, Autor Fecha de publicación: 2023 Artículo en la página: pp. 27-35 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Trastornos del movimiento, Piperazinas, Trastornos psicóticos, Tiazoles. Resumen: This study assessed the efficacy of ziprasidone for the treatment of schizoaffective disorder. Data were taken from subsets of patients with schizoaffective disorder, derived from two separate double-blind, placebo-controlled, parallel-group, multicenter studies. A total of 115 hospitalized patients with an acute episode of schizoaffective disorder were randomly assigned to receive either fixed oral doses of ziprasidone 40 mg/day (N = 16), 80 mg/day (N = 18), 120 mg/day (N = 22), 160 mg/day (N = 25), or placebo (N = 34) for 4 to 6 weeks. Link: ./index.php?lvl=notice_display&id=31134 [artículo] Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies [texto impreso] / Paul E. Keck, Autor ; Karen R. Reeves, Autor ; Edmund P. Harrigan, Autor . - 2023 . - pp. 27-35. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 27-35 Palabras clave: Antipsicóticos, Trastornos del movimiento, Piperazinas, Trastornos psicóticos, Tiazoles. Resumen: This study assessed the efficacy of ziprasidone for the treatment of schizoaffective disorder. Data were taken from subsets of patients with schizoaffective disorder, derived from two separate double-blind, placebo-controlled, parallel-group, multicenter studies. A total of 115 hospitalized patients with an acute episode of schizoaffective disorder were randomly assigned to receive either fixed oral doses of ziprasidone 40 mg/day (N = 16), 80 mg/day (N = 18), 120 mg/day (N = 22), 160 mg/day (N = 25), or placebo (N = 34) for 4 to 6 weeks. Link: ./index.php?lvl=notice_display&id=31134

Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors / Victor Pérez en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 36-45 Título : Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors Tipo de documento: texto impreso Autores: Victor Pérez, Autor ; Dolors Puigdemont, Autor ; Inmaculada Gilaberte, Autor Fecha de publicación: 2023 Artículo en la página: pp. 36-45 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Beta-Antagonistas adrenérgicos, Antidepresivos, Trastorno depresivo mayor, Farmacoterapia, Fluoxetina, Pindolol. Resumen: In a controlled trial, the β-adrenoceptor/5-hydroxytryptamine-1A (5-HT1A) receptor antagonist pindolol accelerated and enhanced the antidepressant effect of fluoxetine. The median times to sustained response (≥50% reduction of baseline severity maintained until endpoint) were 19 days for fluoxetine plus pindolol (N = 55) and 29 days for fluoxetine plus placebo (N = 56) (p = 0.01). Link: ./index.php?lvl=notice_display&id=31135 [artículo] Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors [texto impreso] / Victor Pérez, Autor ; Dolors Puigdemont, Autor ; Inmaculada Gilaberte, Autor . - 2023 . - pp. 36-45. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 36-45 Palabras clave: Beta-Antagonistas adrenérgicos, Antidepresivos, Trastorno depresivo mayor, Farmacoterapia, Fluoxetina, Pindolol. Resumen: In a controlled trial, the β-adrenoceptor/5-hydroxytryptamine-1A (5-HT1A) receptor antagonist pindolol accelerated and enhanced the antidepressant effect of fluoxetine. The median times to sustained response (≥50% reduction of baseline severity maintained until endpoint) were 19 days for fluoxetine plus pindolol (N = 55) and 29 days for fluoxetine plus placebo (N = 56) (p = 0.01). Link: ./index.php?lvl=notice_display&id=31135

Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo / Steven Romano en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 46-52 Título : Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo Tipo de documento: texto impreso Autores: Steven Romano, Autor ; Wayne K Goodman, Autor ; Roy Tamura, Autor Fecha de publicación: 2023 Artículo en la página: pp. 46-52 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antidepresivos, Fluoxetina, Trastorno obsesivo-compulsivo. Resumen: Few controlled studies have evaluated the long-term continuation of pharmacotherapy for relapse prevention in patients with obsessive-compulsive disorder (OCD). This study assessed efficacy and safety of fluoxetine versus placebo in preventing relapse of OCD during a 52-week period in responders to short-term administration of fluoxetine. Link: ./index.php?lvl=notice_display&id=31136 [artículo] Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo [texto impreso] / Steven Romano, Autor ; Wayne K Goodman, Autor ; Roy Tamura, Autor . - 2023 . - pp. 46-52. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 46-52 Palabras clave: Antidepresivos, Fluoxetina, Trastorno obsesivo-compulsivo. Resumen: Few controlled studies have evaluated the long-term continuation of pharmacotherapy for relapse prevention in patients with obsessive-compulsive disorder (OCD). This study assessed efficacy and safety of fluoxetine versus placebo in preventing relapse of OCD during a 52-week period in responders to short-term administration of fluoxetine. Link: ./index.php?lvl=notice_display&id=31136

Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study / Raffaella Zanardi en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 53-58 Título : Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study Tipo de documento: texto impreso Autores: Raffaella Zanardi, Autor ; Francesc Artigas, Autor ; Rosamaria Moresco, Autor Fecha de publicación: 2023 Artículo en la página: pp. 53-58 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Depresión, Paroxetina, Corteza prefrontal, Receptores, Serotonina. Resumen: The changes in aminergic receptors elicited by antidepressant treatments have been extensively examined in the brain of experimental animals using radioligand and molecular techniques. However, there is a very limited direct information regarding the changes effected by such treatments in the human brain, as well as its relationship to clinical improvement. Link: ./index.php?lvl=notice_display&id=31137 [artículo] Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study [texto impreso] / Raffaella Zanardi, Autor ; Francesc Artigas, Autor ; Rosamaria Moresco, Autor . - 2023 . - pp. 53-58. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 53-58 Palabras clave: Depresión, Paroxetina, Corteza prefrontal, Receptores, Serotonina. Resumen: The changes in aminergic receptors elicited by antidepressant treatments have been extensively examined in the brain of experimental animals using radioligand and molecular techniques. However, there is a very limited direct information regarding the changes effected by such treatments in the human brain, as well as its relationship to clinical improvement. Link: ./index.php?lvl=notice_display&id=31137

Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group / Hans Jürgen Möller en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 59-65 Título : Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group Tipo de documento: texto impreso Autores: Hans Jürgen Möller, Autor ; Hans Peter Volz, Autor ; Ingrid W. Reimann, Autor Fecha de publicación: 2023 Artículo en la página: pp. 59-65 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Alprazolam, Ansiolíticos, Antidepresivos, Trastornos de ansiedad, Opipramol. Resumen: Opipramol, a drug widely prescribed in Germany, is a tricyclic compound with no reuptake-inhibiting properties. However, it has pronounced D2-, 5-HT2-, and H1-blocking potential and high affinity to sigma receptors (sigma-1 and sigma-2). In early controlled trials, anxiolytic effects were revealed. However, those studies were performed before the concept of generalized anxiety disorder (GAD) was established. Link: ./index.php?lvl=notice_display&id=31138 [artículo] Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group [texto impreso] / Hans Jürgen Möller, Autor ; Hans Peter Volz, Autor ; Ingrid W. Reimann, Autor . - 2023 . - pp. 59-65. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 59-65 Palabras clave: Alprazolam, Ansiolíticos, Antidepresivos, Trastornos de ansiedad, Opipramol. Resumen: Opipramol, a drug widely prescribed in Germany, is a tricyclic compound with no reuptake-inhibiting properties. However, it has pronounced D2-, 5-HT2-, and H1-blocking potential and high affinity to sigma receptors (sigma-1 and sigma-2). In early controlled trials, anxiolytic effects were revealed. However, those studies were performed before the concept of generalized anxiety disorder (GAD) was established. Link: ./index.php?lvl=notice_display&id=31138

No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a [h215o]-positron emission tomography study / Alex Gamma en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 66-71 Título : No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a [h215o]-positron emission tomography study Tipo de documento: texto impreso Autores: Alex Gamma, Autor ; Alfred Buck, Autor ; Thomas Berthold, Autor Fecha de publicación: 2023 Artículo en la página: pp. 66-71 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Excitación, Cerebro - diagnóstico por imágenes, Cerebro - fisiología, Cognición, Depresión, Alucinógenos, Radioisótopos de oxígeno, Trastornos relacionados con sustancias. Resumen: The long-term use of the serotonin-releaser and uptake-inhibitor 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") has been associated with memory impairments and increased liability to depressive mood and anxiety attacks. It is unclear, however, whether these psychologic deviations are reflected in alterations of the underlying neurophysiologic substrate. Link: ./index.php?lvl=notice_display&id=31139 [artículo] No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a [h215o]-positron emission tomography study [texto impreso] / Alex Gamma, Autor ; Alfred Buck, Autor ; Thomas Berthold, Autor . - 2023 . - pp. 66-71. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 66-71 Palabras clave: Excitación, Cerebro - diagnóstico por imágenes, Cerebro - fisiología, Cognición, Depresión, Alucinógenos, Radioisótopos de oxígeno, Trastornos relacionados con sustancias. Resumen: The long-term use of the serotonin-releaser and uptake-inhibitor 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") has been associated with memory impairments and increased liability to depressive mood and anxiety attacks. It is unclear, however, whether these psychologic deviations are reflected in alterations of the underlying neurophysiologic substrate. Link: ./index.php?lvl=notice_display&id=31139

Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism / Raymond F. Anton en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 72-77 Título : Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism Tipo de documento: texto impreso Autores: Raymond F. Anton, Autor ; Darlene H. Moak, Autor ; Patricia K. Latham, Autor Fecha de publicación: 2023 Artículo en la página: pp. 72-77 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Alcoholismo, Terapia de conducta cognitiva, Terapia de modalidad combinada, Naltrexona, Antagonistas narcóticos. Resumen: Naltrexone, an opiate antagonist medication, has been reported to be efficacious in the treatment of alcohol dependence when added to psychosocial treatments. Although the within-treatment efficacy of naltrexone has received primary attention, there has been little published on the outcome of individuals once the medication is discontinued. Link: ./index.php?lvl=notice_display&id=31140 [artículo] Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism [texto impreso] / Raymond F. Anton, Autor ; Darlene H. Moak, Autor ; Patricia K. Latham, Autor . - 2023 . - pp. 72-77. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 72-77 Palabras clave: Alcoholismo, Terapia de conducta cognitiva, Terapia de modalidad combinada, Naltrexona, Antagonistas narcóticos. Resumen: Naltrexone, an opiate antagonist medication, has been reported to be efficacious in the treatment of alcohol dependence when added to psychosocial treatments. Although the within-treatment efficacy of naltrexone has received primary attention, there has been little published on the outcome of individuals once the medication is discontinued. Link: ./index.php?lvl=notice_display&id=31140

The relationship between mood state and plasma methadone concentration in maintenance patients / Kyle R. Dyer en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 78-84 Título : The relationship between mood state and plasma methadone concentration in maintenance patients Tipo de documento: texto impreso Autores: Kyle R. Dyer, Autor ; Jason M. White, Autor ; David J.R. Foster, Autor Fecha de publicación: 2023 Artículo en la página: pp. 78-84 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Analgésicos, Opioides, Metadona, Trastornos relacionados con opioides, Síndrome de abstinencia de sustancias. Resumen: Although methadone maintenance is designed to stabilize opioid-dependent patients, some experience significant withdrawal in the latter part of the 24-hour interdosing interval. This study was designed to determine the mood changes that maybe associated with such withdrawal. Eighteen methadone patients, nine of whom experienced significant withdrawal, were tested over a single interdosing interval. Link: ./index.php?lvl=notice_display&id=31141 [artículo] The relationship between mood state and plasma methadone concentration in maintenance patients [texto impreso] / Kyle R. Dyer, Autor ; Jason M. White, Autor ; David J.R. Foster, Autor . - 2023 . - pp. 78-84. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 78-84 Palabras clave: Analgésicos, Opioides, Metadona, Trastornos relacionados con opioides, Síndrome de abstinencia de sustancias. Resumen: Although methadone maintenance is designed to stabilize opioid-dependent patients, some experience significant withdrawal in the latter part of the 24-hour interdosing interval. This study was designed to determine the mood changes that maybe associated with such withdrawal. Eighteen methadone patients, nine of whom experienced significant withdrawal, were tested over a single interdosing interval. Link: ./index.php?lvl=notice_display&id=31141